Baidu
map

AGA指南在胰腺囊肿检出进展期肿瘤方面准确性欠佳

2016-06-16 高晓方 译 中国医学论坛报

美国一项研究表明,美国胃肠病学会(AGA)指南在胰腺囊肿检出进展期肿瘤方面的准确性欠佳,综合分子检测的替代方法更具应用前景,但仍需进一步验证。论文发表于《消化内镜》杂志6月刊[Gastrointest Endosc2016,83(6):1107]。        该研究纳入225例因胰腺囊肿接受超声内镜引导下细针穿刺抽吸(EUS-FNA)检查的患者


美国一项研究表明,美国胃肠病学会(AGA)指南在胰腺囊肿检出进展期肿瘤方面的准确性欠佳,综合分子检测的替代方法更具应用前景,但仍需进一步验证。论文发表于《消化内镜》杂志6月刊[Gastrointest Endosc2016,83(6):1107]。
        
该研究纳入225例因胰腺囊肿接受超声内镜引导下细针穿刺抽吸(EUS-FNA)检查的患者,评估患者的临床表现、超声内镜特征、细胞病理学结果、癌胚抗原和胰腺囊肿液分子检测结果。分子检测包括评估热点突变以及KRAS、GNAS、VHL、TP53、PIK3CA和PTEN基因缺失。
       
结果显示,41例(18%)患者具备病理诊断结果,其中13例(6%)为进展期肿瘤。在上述病例中,AGA指南确定进展期肿瘤的敏感性、特异性、阳性预测值和阴性预测值分别为62%、79%、57%和82%。此外,AGA指南漏诊了45%的腺癌或高度不典型增生的导管内乳头状黏液瘤(IPMN)。在无病理结果证实的184例患者中,依据AGA指南,27例(15%)超声内镜发现和(或)具有VHL基因改变的浆液性囊腺瘤(SCA)患者将继续磁共振成像(MRI)监测。与之相比,胰腺囊肿液分子检测的新路径检出进展期肿瘤的敏感性、特异性、阳性预测值和阴性预测值分别为100%、90%、79%和100%。
       
■专家点评
  
AGA指南虽不完美但简单实用,新路径价值仍须探讨
        
上海交通大学医学院附属瑞金医院消化科 袁耀宗 何相宜
       
胰腺囊肿包括先天性、炎症性、肿瘤性等众多类型,其中良性囊肿如假性囊肿、SCA及癌前病变如IPMN、黏液性囊性肿瘤(MCN)最为常见。10多年来,胰腺囊肿的临床处理一直颇具争议。
       
2006年,国际胰腺学会发表了处理IPMN和MCN的指南,提出对小于3cm的囊肿进行随访,手术切除≥3cm或有症状、高危征象或细胞学呈恶性的囊肿。该指南对进展期肿瘤诊断缺乏特异性,故修订版指南于2012年问世,对胰腺囊肿的处理不仅要基于肿瘤大小,还强调了临床症状和高危征象。随后的研究显示,该指南提高了对进展期肿瘤的诊断特异性,但降低了敏感性。此外,上述两项指南均针对IPMN和MCN,对囊肿的临床指导信息较少,较难推广。2015年,AGA基于循证医学证据发布了《无症状肿瘤性胰腺囊肿诊断与管理指南》,因其提高了胰腺囊肿的手术指征,扩大了随访人群而颇具争议。因此,有学者认为AGA指南可能对进展期肿瘤的界定不够准确,对胰腺囊肿的随访并非必要。
        
上述研究的结果显示,AGA指南诊断进展期肿瘤的敏感性为62%、特异性为79%、阳性预测值为57%、阴性预测值为82%。此外,45%的IPMN合并腺癌或高级别上皮内瘤变被漏诊,而15%的SCA却需继续行MRI随访。为提高进展期肿瘤的诊断能力,研究者通过分析建立新的分流随访路径,诊断敏感性达100%、特异性为90%、阳性预测值为79%、阴性预测值为100%。与AGA指南不同,新路径结合了2012年国际胰腺学会修订版和2015年AGA指南,降低了初始行EUS-FNA检查的阈值,即胰腺囊肿只需符合以下1项条件:囊肿大小≥1.5cm、主胰管扩张、壁结节、胰腺囊肿相关的临床症状以及胰腺癌家族史即可行EUS-FNA检查。另一个重要的变更为新路径结合了特异性、敏感性均更高的分子检测手段,例如SCA常有VHL基因突变,而KRAS和GNAS则通常发生在IPMN中。
        
虽然2015年AGA指南的敏感性、特异性尚不完美,但对临床医生而言,具有简单实用的价值。而上述研究中提出的新分流路径虽提高了敏感性、特异性,但研究数据仅来自于1所医院,并且分子检测手段目前难以在我国广泛开展。因此,这一新路径的临床价值仍需要进一步探讨。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=954973, encodeId=3a159549e3af, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e155412415, createdName=ms8000000054312428, createdTime=Wed Apr 07 17:18:47 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905889, encodeId=b1461905889f0, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Sep 09 21:52:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814027, encodeId=6330181402ec8, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Apr 11 15:52:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062356, encodeId=4369206235627, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Mar 15 00:52:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90450, encodeId=450f904502e, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:22:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340739, encodeId=2d621340e394e, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604498, encodeId=7f3b16044981d, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2021-04-07 ms8000000054312428

    很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=954973, encodeId=3a159549e3af, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e155412415, createdName=ms8000000054312428, createdTime=Wed Apr 07 17:18:47 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905889, encodeId=b1461905889f0, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Sep 09 21:52:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814027, encodeId=6330181402ec8, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Apr 11 15:52:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062356, encodeId=4369206235627, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Mar 15 00:52:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90450, encodeId=450f904502e, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:22:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340739, encodeId=2d621340e394e, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604498, encodeId=7f3b16044981d, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=954973, encodeId=3a159549e3af, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e155412415, createdName=ms8000000054312428, createdTime=Wed Apr 07 17:18:47 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905889, encodeId=b1461905889f0, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Sep 09 21:52:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814027, encodeId=6330181402ec8, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Apr 11 15:52:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062356, encodeId=4369206235627, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Mar 15 00:52:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90450, encodeId=450f904502e, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:22:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340739, encodeId=2d621340e394e, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604498, encodeId=7f3b16044981d, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=954973, encodeId=3a159549e3af, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e155412415, createdName=ms8000000054312428, createdTime=Wed Apr 07 17:18:47 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905889, encodeId=b1461905889f0, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Sep 09 21:52:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814027, encodeId=6330181402ec8, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Apr 11 15:52:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062356, encodeId=4369206235627, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Mar 15 00:52:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90450, encodeId=450f904502e, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:22:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340739, encodeId=2d621340e394e, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604498, encodeId=7f3b16044981d, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2017-03-15 vera_1203
  5. [GetPortalCommentsPageByObjectIdResponse(id=954973, encodeId=3a159549e3af, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e155412415, createdName=ms8000000054312428, createdTime=Wed Apr 07 17:18:47 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905889, encodeId=b1461905889f0, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Sep 09 21:52:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814027, encodeId=6330181402ec8, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Apr 11 15:52:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062356, encodeId=4369206235627, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Mar 15 00:52:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90450, encodeId=450f904502e, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:22:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340739, encodeId=2d621340e394e, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604498, encodeId=7f3b16044981d, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
    2016-06-18 沉心多思

    好文章,值得学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=954973, encodeId=3a159549e3af, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e155412415, createdName=ms8000000054312428, createdTime=Wed Apr 07 17:18:47 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905889, encodeId=b1461905889f0, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Sep 09 21:52:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814027, encodeId=6330181402ec8, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Apr 11 15:52:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062356, encodeId=4369206235627, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Mar 15 00:52:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90450, encodeId=450f904502e, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:22:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340739, encodeId=2d621340e394e, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604498, encodeId=7f3b16044981d, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=954973, encodeId=3a159549e3af, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e155412415, createdName=ms8000000054312428, createdTime=Wed Apr 07 17:18:47 CST 2021, time=2021-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905889, encodeId=b1461905889f0, content=<a href='/topic/show?id=34953120e52' target=_blank style='color:#2F92EE;'>#准确性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31207, encryptionId=34953120e52, topicName=准确性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Fri Sep 09 21:52:00 CST 2016, time=2016-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814027, encodeId=6330181402ec8, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Tue Apr 11 15:52:00 CST 2017, time=2017-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062356, encodeId=4369206235627, content=<a href='/topic/show?id=2198208e64' target=_blank style='color:#2F92EE;'>#AGA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2087, encryptionId=2198208e64, topicName=AGA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644e456, createdName=vera_1203, createdTime=Wed Mar 15 00:52:00 CST 2017, time=2017-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90450, encodeId=450f904502e, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:22:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1340739, encodeId=2d621340e394e, content=<a href='/topic/show?id=74a140404de' target=_blank style='color:#2F92EE;'>#囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40404, encryptionId=74a140404de, topicName=囊肿)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=32a12500167, createdName=12498ca5m83暂无昵称, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1604498, encodeId=7f3b16044981d, content=<a href='/topic/show?id=6caf83951ab' target=_blank style='color:#2F92EE;'>#胰腺囊肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83951, encryptionId=6caf83951ab, topicName=胰腺囊肿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e8d19200231, createdName=wenzhiren, createdTime=Sat Jun 18 10:52:00 CST 2016, time=2016-06-18, status=1, ipAttribution=)]

相关资讯

PNAS:诊断胰腺囊肿的新方法

美国约翰霍普金斯大学的Bert Vogelstein等在美国国家科学院院刊(Proceedings of the National Academy of Sciences)上发布文章称,通过对4种常见胰腺囊肿进行DNA分析,发现每种囊肿均有不同的基因突变。这一发现将使胰腺囊肿的诊断更为简单、便捷。 美国约有2%的人口患有胰腺囊肿,其中一部分需要手术切除并进行病理分析,以判断其是否有恶变倾向。胰腺

JACS:研究发现可诊断良性胰腺囊肿标记物

来自印第安纳大学医学院的研究人员近日发现了一种可以用于诊断胰腺良性囊肿的准确性较高的无创检查方法。该技术通过对胰腺囊肿囊液进行分析,可以明确有恶变倾向的胰腺良性囊肿的常见类型。相关研究于2013年12月24日在线发表在 J Am Coll Surg 杂志上。 新型的生物标记物为胰腺囊肿囊液中同种异型血管内皮生长因子A(VEGF-A),在临床中对接受内镜检查的胰腺囊肿患者会常规行胰液检查。研究人员

Baidu
map
Baidu
map
Baidu
map